Tags

Type your tag names separated by a space and hit enter

[High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means].
Med Clin (Barc). 1995 Oct 07; 105(11):407-11.MC

Abstract

BACKGROUND

In the last years high dose chemotherapy (HDC) schedules have been developed with autologous bone marrow transplantation (ABMT) which are very effective in breast cancer. Expectation has been raised concerning the cure of a subgroup of patients with metastatic breast cancer and the improvement of prognosis in high risk stages II and III.

METHODS

CTCb (cyclophosphamide 6 g/m2, thiotepa 500 mg/m2 and carboplatin 800 mg/m2) was administered with autologous peripheral hematopoietic progenitor cells transplantation (TACPHP) and granulocytic colony stimulating factor (G-CSF) 5 micrograms/kg/day to 27 patients with breast cancer: 9 in stage IV in complete remission, 12 in stage II with > or = 10 affected lymph nodes and 6 in stage III.

RESULTS

No toxic deaths were reported. The median time to achieve > or = 0.5 x 10(9) neutrophils/l was 8 days, to > or = 20 x 10(9) platelets/l 9 days and to > or = 50 x 10(9) platelets/l 12 days. Fever was observed in 85% of the patients although its median duration was of only one day. Extrahematologic toxicity was moderate with grade III nausea/vomiting in 48% of patients, grade III mucositis in 22%, grade III hepatitis in 19%, and grade III diarrhea in 4%. No grade IV toxicity was observed. The median follow-up is still short (10 months, range: 2-25). All the patients maintain normal hematologic peripheral blood counts and only 4 (in stage IV) have relapsed.

CONCLUSIONS

The slight extrahematologic toxicity observed in the high dose chemotherapy with cyclophosphamide, thiotepa and carboplatin, and the rapid hematologic recovery provided by the TACPHP and G-CSF allow the above schedule to be administered with moderate toxicity and no mortality. This low toxic profile leads to the possibility of future trials with this chemotherapy schedule in other subgroups of patients with breast cancer.

Authors+Show Affiliations

Departamento de Oncología, Hospital de la Santa Creu i Sant Pau, Barcelona.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

spa

PubMed ID

7475451

Citation

Sola Rocabert, C, et al. "[High-dosage Chemotherapy and the Autologous Transplantation of Peripheral Hematopoietic Progenitor Cells in Breast Cancer: the Initial Results, Analysis of Toxicity and the Necessary Support Means]." Medicina Clinica, vol. 105, no. 11, 1995, pp. 407-11.
Sola Rocabert C, Mesía R, Mendoza L, et al. [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means]. Med Clin (Barc). 1995;105(11):407-11.
Sola Rocabert, C., Mesía, R., Mendoza, L., Tabernero, J. M., Amill, B., Maroto, P., Bellet, M., Ojeda, B., Alonso, M. C., & Verger, G. (1995). [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means]. Medicina Clinica, 105(11), 407-11.
Sola Rocabert C, et al. [High-dosage Chemotherapy and the Autologous Transplantation of Peripheral Hematopoietic Progenitor Cells in Breast Cancer: the Initial Results, Analysis of Toxicity and the Necessary Support Means]. Med Clin (Barc). 1995 Oct 7;105(11):407-11. PubMed PMID: 7475451.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means]. A1 - Sola Rocabert,C, AU - Mesía,R, AU - Mendoza,L, AU - Tabernero,J M, AU - Amill,B, AU - Maroto,P, AU - Bellet,M, AU - Ojeda,B, AU - Alonso,M C, AU - Verger,G, PY - 1995/10/7/pubmed PY - 1995/10/7/medline PY - 1995/10/7/entrez SP - 407 EP - 11 JF - Medicina clinica JO - Med Clin (Barc) VL - 105 IS - 11 N2 - BACKGROUND: In the last years high dose chemotherapy (HDC) schedules have been developed with autologous bone marrow transplantation (ABMT) which are very effective in breast cancer. Expectation has been raised concerning the cure of a subgroup of patients with metastatic breast cancer and the improvement of prognosis in high risk stages II and III. METHODS: CTCb (cyclophosphamide 6 g/m2, thiotepa 500 mg/m2 and carboplatin 800 mg/m2) was administered with autologous peripheral hematopoietic progenitor cells transplantation (TACPHP) and granulocytic colony stimulating factor (G-CSF) 5 micrograms/kg/day to 27 patients with breast cancer: 9 in stage IV in complete remission, 12 in stage II with > or = 10 affected lymph nodes and 6 in stage III. RESULTS: No toxic deaths were reported. The median time to achieve > or = 0.5 x 10(9) neutrophils/l was 8 days, to > or = 20 x 10(9) platelets/l 9 days and to > or = 50 x 10(9) platelets/l 12 days. Fever was observed in 85% of the patients although its median duration was of only one day. Extrahematologic toxicity was moderate with grade III nausea/vomiting in 48% of patients, grade III mucositis in 22%, grade III hepatitis in 19%, and grade III diarrhea in 4%. No grade IV toxicity was observed. The median follow-up is still short (10 months, range: 2-25). All the patients maintain normal hematologic peripheral blood counts and only 4 (in stage IV) have relapsed. CONCLUSIONS: The slight extrahematologic toxicity observed in the high dose chemotherapy with cyclophosphamide, thiotepa and carboplatin, and the rapid hematologic recovery provided by the TACPHP and G-CSF allow the above schedule to be administered with moderate toxicity and no mortality. This low toxic profile leads to the possibility of future trials with this chemotherapy schedule in other subgroups of patients with breast cancer. SN - 0025-7753 UR - https://www.unboundmedicine.com/medline/citation/7475451/[High_dosage_chemotherapy_and_the_autologous_transplantation_of_peripheral_hematopoietic_progenitor_cells_in_breast_cancer:_the_initial_results_analysis_of_toxicity_and_the_necessary_support_means]_ L2 - http://www.diseaseinfosearch.org/result/960 DB - PRIME DP - Unbound Medicine ER -